(lp0
S'The Main Reason Achillion Pharmaceuticals, Inc. Collapsed 34% in November Motley Fool - Dec 5, 2016 Shares of Achillion Pharmaceuticals , a developmental-stage developer of small-molecule drugs to treat autoimmune diseases and infectious diseases such as hepatitis C, plummeted 34% in November, according to data from S&amp;P Global&nbsp;...Achillion Pharma  Announces Presentation of Novel Research Related to ... - StreetInsider.com'
p1
aS"Is It Time to go for Nimble Storage, Inc. , Achillion Pharmaceuticals ... StockNewsJournal - 16 hours ago Achillion Pharmaceuticals, Inc. , maintained return on investment for the last twelve months at -14.52, higher than what Reuters data shows regarding industry's average.ACADIA Pharmaceuticals Inc. , Achillion Pharmaceuticals, Inc. (ACHN ... - The USA CommerceIf You Lack Direction On Achillion Pharmaceuticals, Inc. , You Need to ... - USA Commerce Daily"
p2
aS'Achillion Pharmaceuticals - Taking Its First Steps After HCV Seeking Alpha - Dec 25, 2016 Achillion Pharmaceuticals, Inc.  is a clinical stage biopharmaceutical company with drugs being developed primarily in the hepatitis C virus and complement factor pathway disease areas.'
p3
aS'BRIEF-Achillion Pharmaceuticals Inc says files for mixed shelf of upto $250 ... Reuters - Feb 23, 2017 LONDON, March 10 Investors expect the European Central Bank to raise interest rates by March 2018, money market prices show, with some banks forecasting multiple hikes in 2018 on expectations the central bank will wind down stimulus as the European&nbsp;...'
p4
aS'Achillion Pharmaceuticals Inc.  Plunges 8.96% on February 24 Equities.com - Feb 24, 2017 Achillion Pharmaceuticals Inc.  had a rough trading day for Friday February 24 as shares tumbled 8.96%, or a loss of $-0.38 per share, to close at $3.86.Why Did Shares Of Achillion Pharmaceuticals, Inc.  Plunge 9%? - StockNewsUnionAchillion  Reports Narrower-Than-Expected Q4 Loss - Yahoo Finance'
p5
aS'Achillion Pharmaceuticals Inc.  Settles Into New 52-Week Low on February ... Equities.com - Feb 24, 2017 Shares of Achillion Pharmaceuticals Inc.  sank into a new 52-week low yesterday, and could be a company to watch at the open.'
p6
aS"Option Market: Achillion Pharmaceuticals Inc Risk Hits An Elevated Level CML News - Feb 28, 2017 We're going to look at a proprietary risk rating for the next 30-days built by Capital Market Laboratories  based on a large number of interactions of data points, many of which come directly from the option market for Achillion Pharmaceuticals ..."
p7
aS'Achillion Pharma  Granted USPTO Matter Patent for Small Molecule ... StreetInsider.com - Mar 21, 2017 Achillion Pharmaceuticals, Inc.  today announced that the U.S. Patent and Trademark Office  has issued the first U.S.'
p8
aS'Achillion Pharmaceuticals, Inc. : How technical indicators have come out? Post Analyst - 18 hours ago Achillion Pharmaceuticals, Inc.  traded at an unexpectedly high level on 03/21/2017 when the stock experienced a -4.24 loss to a closing price of $3.84.'
p9
aS'Achillion Pharmaceuticals Inc Stock Volatility Hits An Escalated Level CML News - Feb 24, 2017 This is a proprietary realized volatility rating created by Capital Market Laboratories  based on a large number of data interactions for Achillion Pharmaceuticals Inc  . We examine the little used gem of daily stock volatility ...'
p10
a.